文献速递前列腺癌

预测转移性去势抵抗性前列腺癌中多西他赛毒性相关停药与总生存:开放三期临床试验数据的汇总分析

Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-02-02

本研究利用三项前线mCRPC试验(ASCENT2、VENICE、MAINSAIL)对照组的1568例患者个体数据,建立竞争风险回归模型预测毒性相关多西他赛停药(TRDD),并通过CART分析划分风险组。结果显示12个月内TRDD合并累积发生率为19%,三个风险组的TRDD概率分别为14%、58%、79%,中位OS分别为24、20、13个月(p < 0.001)。模型有助于临床平衡多西他赛的毒性与疗效。

要点

  • 基于年龄、ECOG PS、AST、胆红素、镇痛药使用、糖尿病和CKD构建TRDD预测模型。
  • CART划分低(≤24%)、中(25-64%)、高(≥65%)风险组,TRDD概率分别为14%、58%、79%。
  • 三组中位OS分别为24、20、13个月(p < 0.001),风险分层与生存相关。

核心结论

  • 基于常规临床变量构建的模型可预测mCRPC患者毒性相关多西他赛停药风险。
  • 模型划分的三个风险组与总生存相关,有助于共享决策。

研究设计与样本

  • 汇总分析三项前线mCRPC三期试验(ASCENT2、VENICE、MAINSAIL)对照组个体患者数据,共1568例。
  • 采用竞争风险回归预测TRDD,并以CART分析划分风险组。

主要发现

  • 12个月内TRDD合并累积发生率为19%,竞争事件包括死亡474例和进展59例。
  • 风险回归模型最终纳入年龄、ECOG体能状态、AST、胆红素、镇痛药使用、糖尿病和慢性肾脏病。
  • 低、中、高风险组TRDD概率分别为14%、58%、79%,中位OS分别为24、20、13个月(p < 0.001)。

关键数值与推荐

  • 低风险组:模型衍生TRDD风险≤24%;中风险组:25-64%;高风险组:≥65%。

临床怎么用

  • 可利用该模型评估mCRPC患者多西他赛毒性相关停药风险,辅助治疗选择与共享决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Docetaxel is widely used in metastatic castration-resistant prostate cancer (mCRPC), however its optimal use remains unclear in the current treatment landscape. Biomarkers to predict Docetaxel toxicity may help optimize treatment selection. We aimed to create a predictive model for toxicity-related Docetaxel discontinuation (TRDD). METHODS: Through Project Data Sphere, we accessed individual patient data from the control arms of three frontline mCRPC trials: ASCENT2, VENICE, and MAINSAIL. The inclusion criteria for these trials were all similar and included patients with chemotherapy-naïve mCRPC. The primary outcome was occurrence of TRDD. A competing risks regression (CRR) was used to predict TRDD, after accounting for the occurrence of competing events (death or progression). The output of the model was used as the dependent variable on a classification and regression tree (CART) to identify risk groups for TRDD. RESULTS: Overall, 1568 patients were considered. Pooled CI of TRDD was 19% after accounting for competing events (death: 474; progression: 59) within 12 months of starting treatment. To build a risk calculator we relied on a CRR that ultimately included age, ECOG performance status, AST, bilirubin, use of analgesics, and presence of diabetes and chronic kidney disease. The CART analysis identified three risk groups that were named: low (model-derived TRDD risk ≤24%), intermediate (25-64%), and high (≥65%) risk group. In each risk group, probability of TRDD during treatment was 14%, 58%, and 79%, and median OS was 24 months, 20 months, and 13 months, respectively (p < 0.001). CONCLUSIONS: Treatment selection in mCRPC remains a challenge. Our model can help clinicians balance Docetaxel toxicity and efficacy. The three risk categories that we identified correlated with OS and this is particularly useful for an optimal shared decision-making process.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Martini A, Parikh AB, Sfakianos JP, et al. Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. Prostate Cancer Prostatic Dis. 2021. PMID: 33531652. doi:10.1038/s41391-021-00326-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。